FDA to review Eisai’s sNDA for antiepileptic drug perampanel to treat PGTC seizures
Fycompa is an oral medication and is the first FDA-approved non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor antagonist. Perampanel CIII was approved by the FDA in October 2012 and